Norbert Bischofberger

Norbert Bischofberger, former CSO of Gilead, discusses antiviral opportunities, Gilead's pivot to oncology and the need for a societal discussion of drug costs.

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097445/
https://www.ncbi.nlm.nih.gov/pubmed/29844601
http://dx.doi.org/10.1038/nrd.2018.82

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097445/
https://www.ncbi.nlm.nih.gov/pubmed/29844601
http://dx.doi.org/10.1038/nrd.2018.82

Ejemplares similares